David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Benjamin Eye Institute, Los Angeles, California.
Retina. 2018 Feb;38(2):292-298. doi: 10.1097/IAE.0000000000001546.
Anti-vascular endothelial growth factor therapy has improved the prognosis for patients with central retinal vein occlusion (CRVO). However, most studies published to date exclude ischemic CRVO. The purpose of this study was to describe the outcome in eyes with ischemic CRVO treated with anti-vascular endothelial growth factor therapy.
Thirty-seven patients with ischemic CRVO from 3 centers were followed for at least 6 months. Data on patient demographic, vision status, and anti-vascular endothelial growth factor treatments were collected.
Average number of injections during the study period was 5. Younger age was associated with improved vision (P = 0.006). Patients with improved visual outcomes tended to have macular edema as the primary indication for treatment, whereas patients with worse outcomes tended to have neovascularization as the primary indication for treatment.
This study highlights significant variability in the use of anti-vascular endothelial growth factor therapy for ischemic CRVO and underscores that eyes with neovascularization tend to have worse visual outcomes.
抗血管内皮生长因子治疗改善了视网膜中央静脉阻塞（CRVO）患者的预后。然而，迄今为止发表的大多数研究都排除了缺血性 CRVO。本研究旨在描述接受抗血管内皮生长因子治疗的缺血性 CRVO 患者的结局。
来自 3 个中心的 37 例缺血性 CRVO 患者至少随访 6 个月。收集患者的人口统计学、视力状况和抗血管内皮生长因子治疗的数据。
研究期间的平均注射次数为 5 次。年龄较小与视力改善相关（P = 0.006）。视力改善的患者倾向于以黄斑水肿为主要治疗指征，而视力恶化的患者倾向于以新生血管为主要治疗指征。
本研究强调了抗血管内皮生长因子治疗缺血性 CRVO 的使用存在显著差异，并强调了存在新生血管的眼睛往往视力预后更差。
